recurrent wheezing Efficacy,
Conditions
Interventions
fluticasone propionate (IFP) MDI 125 mcg via cone spacer twice daily.,salmeterol/fluticasone propionate (ISFP) 25/125 mcg via cone spacer twice daily started at the onset of symptoms or signs of respi
6 puffs when having exacerbation.
Active Comparator Drug,Experimental Drug
Daily inhaled fluticasone propionate,episodic inhaled salmeterol/fluticasone propionate
Sponsors
Queen Sirikit National Institute of Child Health
Eligibility
Sex/Gender
All
Age
1 Years to 15 Years
Inclusion criteria
Inclusion criteria: 1. History of recurrent wheezing at least 3 times/year and at least 2 of 5 symptom patterns tending to be asthma - Cough or wheeze more than 10 days during upper respiratory tract infection - Night worsening symptoms, cough or wheeze triggered by exercise and/or laughing and/or crying - History of atopy such as atopic dermatitis, allergic rhinitis - First degree relatives with asthma - Diagnosed asthma by spirometry
Exclusion criteria
Exclusion criteria: 1. Children who have history of using medications for controlling their recurrent wheezing symptoms such as Inhaled corticosteroids and/or leukotriene receptor antagonists before recruitment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of symptom control 6 months Percentage and time to first exacerbation that needed systemic corticosteroids | — |
Secondary
| Measure | Time frame |
|---|---|
| Growth suppression and safety 6 months Increased height and adverse events | — |
Countries
Thailand
Contacts
Public ContactJiratchaya Chamnanrua
Queen Sirikit National Institute of Child Health
Outcome results
None listed